Stock info Novo Nordisk | Filter  Basic-Info

Stock: Novo Nordisk (Danmark large caps), ISIN: DK0060102614

Last Price 893.90 Max Price 924.50
Min Price 517.00 1 Year return 21.62
Sector Consumer Goods Subsector Personal Goods
Annual report 2015

Loading...

Contact info:Street: Novo AllePostbox: 2880City: BagsvaerdCountry: DenmarkPhone: 45-44-448888Website: www.novonordisk.comCEO: Lars Rebien SoerensenCFO: Jesper Brandgaard

Sector Review Novo Nordisk

Loading...
Year Turnover Total sector Market share
2019 122,021 849,130 14.37 %
2020 126,946 763,401 16.63 %
2021 140,800 886,986 15.87 %
2022 176,954 1,018,101 17.38 %
2023 0 0 0.00 %

Advice Novo Nordisk

No Records Found




News Novo Nordisk

Analysts expect record sales Novo Nordisk

Over the current book year the total revenu from the company based in Bagsvaerd will be 208.18 billion Danish Krone (consensus estimates). The expected revenue would be a record for the company. This is quite more than 2022's revenue of 176.95 billion Danish Krone....

Analysts expect over 2018 decreasing revenue Novo Nordisk

Tomorrow the Danish Novo Nordisk will publish its past quarters figures. For this year Novo Nordisk's revenue will be around 111,52 billion Danish Krone. This is according to the average of the analysts' estimates. This is slightly lower than 2017's revenue of111,7...

Novo Nordisk strong outperformer in Denmark

The past years Novo Nordisk gained a lot in value. The past year the 10 year with a huge profit of 384 percent one of the best shares of Denmark. Since the start of this year, the average Danish stock rose year approximately 50 percent in value. Other winners...

Analysts foresee more revenue Novo Nordisk

Next Monday the Danish company Novo Nordisk will publish its past quarter's results. Over the current book year the total revenue will be 112,71 billion euros (consensus estimates). This is slightly more than 2016's revenue of 111,7 billion euros. Historical...

Annual reports Novo Nordisk

2017 2018 2019 2020 2021

Profile Novo Nordisk

Novo Nordisk

(DK0060102614)/ NOVO B

Novo Nordisk has it' headquarter based in Bagsvaerd. Novo Nordisk is mostly active in the personal goods sector. The CEO of Novo Nordisk is Lars Rebien Soerensen. Jesper Brandgaard runs the company as a CFO. Over the past 10 years the global personal goods companies gained around 51 percent. Measured since 2011 the sector is 36 percent higher and over the past 12 months (December 2015-2016) there is a minus of 51 percent.

The past year was a relatively good year for Novo Nordisk investors

Over the period from December 2015 till December 2016 the stock lost around 35 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 97 percent. Novo Nordisk's revenues between 2011 and 2015 were quite unstable and moved between 22,21 billion euros and 38,29 billion euros. Novo Nordisk's net results between 2011 and 2015 were very fluctuating and moved between 17,1 billion euros and 34,86 billion euros.

Over the past 5 years the Danish company paid out dividends. On average the Novo Nordisk stock yielded a delivered a dividend yield of around 22,3 percent over the past 5 years.

At the end of 2015 Novo Nordisk employed at around 40,96 thousand people.

Novo Nordisk' balance mostly financed with equity

Last year the balance sheet of the Danish company was worth 91,8 billion euros. Last year the total debt of the company was 44,83 billion euros. This equals around 48,83 percent of the total balance sheet. The Danish company's price/earnings-ratio was 21. So the market valued the stock at 21 times the 2015' earnings per share. Based on the classical stock valuation theories the Danish stock can be seen as a value stock.

At the end of 2015 the Danish company's market capitalization equaled around 1029,08 billion euros. At the end of 2015 the Danish company had around 2,6 billion stocks listed on the stock exchange(s).

All Novo Nordisk's annual reports can be found here. More information about Novo Nordisk can be found it's website. .


Results Novo Nordisk

Results
2015
2016
2017
2018
2019
2020
Revenue
107,927
111,780
111,696
111,831
122,021
126,946
Costs
73,067
73,855
73,566
73,203
83,070
84,808
Profit
34,860
37,925
38,130
38,628
38,951
42,138
Margin of profit
32.30
33.93
34.14
34.54
31.92
33.19
ROI
74.22
83.78
76.54
74.52
67.63
66.54

Balance Novo Nordisk

Balance
2015
2016
2017
2018
2019
2020
Equity
46,969
45,269
49,815
51,839
57,593
63,325
Debt
44,830
52,270
52,540
58,930
68,019
81,597
Total assets
91,799
97,539
102,355
110,769
125,612
144,922
Solvency
51.17
46.41
48.67
46.80
45.85
43.70
Cash
20,465
20,699
18,852
15,638
14,966
12,104
Cashflow
38,287
48,314
41,168
45,028
46,782
51,951
Employees
40,000
0
0
0
0
Revenue per employee
2.70
0.0
0.0
0.0
0.0
Cashflow / Debt
0.85
0.92
0.78
0.76
0.69
0.64

Details Novo Nordisk

Details
2016
2017
2018
2019
2020
Price
399.90
254.70
334.50
297.90
386.65
Eps
14.96
15.39
15.93
16.38
18.01
Price/earnings-ratio
26.73
16.55
21.00
18.19
49.63
Dividend
7.60
7.85
8.15
8.35
9.10
Dividend %
1.90 %
3.08 %
2.44 %
2.80 %
1.02 %
Payout %
0.51
0.51
0.51
0.51
0.51
Book value
23.02
26.13
27.92
31.73
35.67
Market to book
0.06
0.10
0.08
0.11
0.04
Cashflow per stock
24.56
21.59
24.25
25.78
29.26
Stocks
1,967
1,907
1,857
1,815
1,776
Market Cap
786.562.01
485.601.85
621.166.50
540.688.50
1.587.119.45

Dividend Novo Nordisk


Price info Novo Nordisk

Date
Price
22 Mar 2024
893.90
18 Mar 2024
914.20
15 Mar 2024
924.50
12 Mar 2024
914.80
11 Mar 2024
905.00
09 Mar 2024
905.00
07 Mar 2024
848.90
01 Mar 2024
819.70
29 Feb 2024
834.10
27 Feb 2024
844.10
22 Feb 2024
830.80
21 Feb 2024
843.30
20 Feb 2024
858.00
15 Feb 2024
846.90
14 Feb 2024
832.30
13 Feb 2024
830.60
09 Feb 2024
813.80
08 Feb 2024
813.80
07 Feb 2024
813.50
06 Feb 2024
809.80
05 Feb 2024
781.40
01 Feb 2024
774.80
31 Jan 2024
774.80
30 Jan 2024
745.70
27 Jan 2024
732.00
25 Jan 2024
725.00
24 Jan 2024
721.10
23 Jan 2024
726.60
16 Jan 2024
725.60
11 Jan 2024
737.90